Holen Sie sich die Stockscreener-App
12.33
0.49%
0.06
Handel nachbörslich:
12.39
0.06
+0.49%
Schlusskurs vom Vortag:
$12.27
Offen:
$12.325
24-Stunden-Volumen:
40,027
Relative Volume:
2.37
Marktkapitalisierung:
$254.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+5.75%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.17
$12.57
1-Wochen-Bereich:
$11.72
$13.39
52-Wochen-Spanne:
$10.72
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Firmenname
Satellos Bioscience Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
12.33 | 253.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Satellos Bioscience Inc Aktie (MSLE) Neueste Nachrichten
(MSCL) Trading Performance and Risk Management (MSCL:CA)Stock Traders Daily Canada - Stock Traders Daily
MSCLFSatellos Bioscience Inc Latest Stock News & Market Updates - Stock Titan
(MSCL) Strategic Market Analysis (MSCL:CA) - Stock Traders Daily
Satellos Bioscience (MSLE) Stock Analysis Report | Financials & Insights - Benzinga España
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - BioSpace
Stocks in play: Satellos Bioscience Inc. - The Globe and Mail
Satellos Bioscience Inc. - Baystreet.ca
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association - PharmiWeb.com
Satellos to Showcase New SAT-3247 DMD and FSHD Data at 2026 MDA Conference - TipRanks
Satellos (Nasdaq: MSLE) plans SAT-3247 data at 2026 MDA meeting - Stock Titan
(MSCL) Market Insights and Trading Signals (MSCL:CA) - Stock Traders Daily
(MSCL) Technical Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience to Court Investors as Phase 2 DMD Program Advances - TipRanks
Satellos Bioscience (MSLE) highlights SAT-3247 at key investor conferences - Stock Titan
Satellos to Participate in Upcoming Investor Conferences - Investing News Network
Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy - TipRanks
Satellos (NASDAQ: MSLE) sets virtual KOL event on SAT-3247 DMD program - Stock Titan
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy - PharmiWeb.com
Inside Satellos’ experimental DMD pill at live online event - Stock Titan
(MSCL) Equity Trading Insights (MSCL:CA) - Stock Traders Daily
US$57.2M raise and Nasdaq Global Market listing for Satellos Bioscience (NASDAQ: MSLE) - Stock Titan
1st boys dosed in Phase 2 trial of oral DMD treatment SAT-3247 - Muscular Dystrophy News
Satellos to Highlight Duchenne Drug Program at Series of Investor Conferences - TipRanks
(MSCL) Dynamic Trading Report (MSCL:CA) - Stock Traders Daily
United StatesMintz Advises Satellos Bioscience In Its US$57.2 Million Initial US Public Offering - Mondaq
Satellos Bioscience (NASDAQ:MSLE) Upgraded at Zacks Research - Defense World
Total liabilities of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience (MSLE) Stock Chart and Price History 2026 - MarketBeat
Satellos Bioscience (MSLE) Stock Trends and Sentiment 2026 - MarketBeat
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy - Investing News Network
Satellos Bioscience Doses First Patient in Phase 2 Pediatric Duchenne Study of SAT-3247 - TipRanks
Free cash flow per share of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing - Global Legal Chronicle
This Canadian biotech stock is undervalued, analyst says - Cantech Letter
Satellos price target raised to $40 from $5 at Oppenheimer - Yahoo Finance
Satellos Closes US$57.2 Million Public Offering in Canada and the United States - 富途牛牛
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - PharmiWeb.com
Satellos Bioscience to Highlight Muscle-Regeneration Platform at Guggenheim Biotech Summit 2026 - TipRanks
Mintz Advises Satellos Bioscience in its US$57.2 Million Initial US Public Offering - Mintz
Satellos Bioscience Raises US$57.2 Million in Cross-Border Equity Offering to Advance Muscle Disease Pipeline - TipRanks
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares - BioSpace
Latham Advises on Satellos’ US$50 Million Initial US Offering - Legal Desire Media and Insights
Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours - Stocktwits
Satellos Bioscience raises $57.2 million in public offering By Investing.com - Investing.com Canada
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise - pharmiweb.com
Satellos Bioscience Completes $57.2 Million Public Offering - marketscreener.com
Satellos Bioscience raises $57.2 million in public offering - Investing.com
Satellos Brief: Closes US$57.2M Public Offer in Canada and United States, Including Exercise of Underwriters' Option to Purchase Additional Shares - marketscreener.com
Finanzdaten der Satellos Bioscience Inc-Aktie (MSLE)
Es liegen keine Finanzdaten für Satellos Bioscience Inc (MSLE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):